US FDA approves apomorphine sublingual film (Kynmobi) for the treatment of Parkinson’s disease OFF episodes

This novel formulation of apomorphine is the first sublingual therapy for the treatment of OFF episodes in Parkinson’s disease. In a Phase III study it was shown to improve motor symptoms at 30 minutes after dosing; the most common adverse events included oropharyngeal reactions

SPS commentary:

Apomorphine sublingual film has not yet been reviewed by the European Medicines Agency.


Biospace Inc.